Ms. Alison Lawton

Biography

  Ms. Alison Lawton served as the Chief Operating Officer of Aura Biosciences Inc. until December 2017. Ms. Lawton has been an Advisor of Aura Biosciences, Inc. since December 2017. Ms. Lawton is a Corporate Advisor to Visgo Therapeutics. She served as the Chief Operating Officer of X4 Pharmaceuticals Inc., until June 13, 2016. She has more than 30 years of global pharmaceutical and biotechnology experience, including 23 years at Genzyme Corporation and seven years in the U.K. at Warner-Lambert/Parke-Davis. Ms. Lawton served as the Chief Operating Officer at OvaScience, Inc. from January 2013 to January 2014. She served as Head of Genzyme Biosurgery, where she was responsible for its global cell therapy, regenerative medicine, orthopedics and surgical businesses; and head of Global Market Access, with responsibility for regulatory affairs, global health outcomes and strategic pricing, global public policy and global product safety. Ms. Lawton served as General Manager of the Biosurgery business of Genzyme Corporation since May 2010 and served as its Senior Vice President. She was responsible for Genzyme's global orthopedics, biosurgical specialty (BSS) and cell therapy and regenerative medicine (CT&RM) businesses. She served as Senior Vice President and General Manager of the Sanofi Biosurgery Business Unit, where she was responsible for three separate franchises, including surgical, cell therapy and regenerative medicine and orthopedics. She served as Senior Vice President of Global Market Access for Genzyme. She served as Senior Vice President of Regulatory Affairs and Corporate Quality Systems at Genzyme Corporation. She served as Senior Vice President of Regulatory Affairs and Corporate Quality Systems at Genzyme Oncology, Inc. (alternate name, Genzyme Molecular Oncology), a division of Genzyme Corporation. She joined of Genzyme Corporation in 1991. Ms. Lawton has held various positions in Genzyme's regulatory affairs department since she began with Genzyme Corporation, as an international regulatory affairs specialist. She was responsible for all of Genzyme's global regulatory activities and leads Genzyme Corporation's corporate quality systems organization. She worked for eight years at Warner-Lambert, where she gained experience in both regulatory affairs and marketing. Ms. Lawton worked 8 years in the UK at Parke-Davis. She has been an Independent Director of Verastem, Inc. since November 26, 2012. She serves as a Director of MassMEDIC., and Follica, Inc. She has been Member of the Supervisory Board at ProQR Therapeutics N.V. since September 17, 2014. She has been a Member of Corporate Advisory Board at X4 Pharmaceuticals Inc. since April 4, 2016. She has been a Director of Magenta Therapeutics, Inc. since October 24, 2017. She serves on the Scientific Advisory Board for the Massachusetts Life Science Center. She served as a Director of CoLucid Pharmaceuticals, Inc., since March 15, 2016 until March 1, 2017. She served as a Director of Cubist Pharmaceuticals Inc. from February 16, 2012 to January 2015. She served two terms as the industry representative on the U.S. Food and Drug Administration (FDA) Cell & Gene Therapy Advisory Panel. She served as President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for Cell and Gene Therapy Committee. Ms. Lawton has a B.Sc. Hons. Degree in Pharmacology from King's College, University of London.

Research Interest

Pharmaceutical and Biotechnology